Stockbroker tips from ShareCast
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
Broker tips: GSK, Astrazeneca, Vodafone
Tue 15 September 2026 12:54
(Sharecast News) - Analysts at Berenberg upgraded drugmaker GSK from 'hold' to 'buy' on Tuesday and lifted their target price on the stock from £20 to £22, saying recent business‑development activity and pipeline momentum had strengthened the firm
Deutsche Bank upgrades Astrazeneca to 'hold'
Tue 15 September 2026 12:42
(Sharecast News) - Deutsche Bank upgraded Astrazeneca from 'sell' to 'hold' on Tuesday and nudged its price target up from 11,500p to 11,700p, saying the risk‑reward scenario had shifted following last week's negative SERENA-4 readout and a period of un
Berenberg upgrades GSK to 'buy', raises target price
Tue 15 September 2026 07:24
(Sharecast News) - Analysts at Berenberg upgraded drugmaker GSK from 'hold' to 'buy' on Tuesday and lifted their target price on the stock from £20 to £22, saying recent business‑development activity and pipeline momentum had strengthened the firm
Broker tips: Antofagasta, Cerillion
Mon 14 September 2026 13:59
(Sharecast News) - Analysts at Berenberg upgraded Antofagasta from 'hold' to 'buy' on Monday, saying last week's sharp pullback in copper prices had created an attractive entry point, while keeping its 4,400p price target unchanged for around 16% upside.
Canaccord Genuity lowers target price on Cerillion
Mon 14 September 2026 12:36
(Sharecast News) - Canaccord Genuity cut its price target on Cerillion from 2,060p to 1,760p on Monday, after the software group warned that second‑half trading would be weaker than expected, leading to revenue and underlying earnings misses against con
Berenberg upgrades Antofagasta to 'buy'
Mon 14 September 2026 07:48
(Sharecast News) - Analysts at Berenberg upgraded Antofagasta from 'hold' to 'buy' on Monday, saying last week's sharp pullback in copper prices had created an attractive entry point, while keeping its 4,400p price target unchanged for around 16% upside.